Professor Stricker’s team presented their results at the annual scientific meeting at USANZ 2024.
Jason Jung, research fellow, presented his findings on how irreversible electroporation (IRE) of intermediate risk prostate cancer mitigates immune suppression and induces systemic c antitumor T cell activation. Essentially IRE focal therapy creates a prostate cancer immune response possibly turning the cancer into a “hot” tumour which may respond to immunotherapy. The manuscript of this landmark study has been submitted to Nature Review